Mizuho Securities Upgrades Jazz Pharmaceuticals (JAZZ) to Buy on Xyrem Settlements

Mizuho Securities upgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Neutral to Buy with a price target of $193.00 (from $137.00) on Xyrem Settlements.

Analyst Irina Koffler commented, "Jazz's announcement of its late 2025 Xyrem settlements was the upgrade signal we were looking for. We modeled Xyrem exclusivity through 2025 and lowered the WACC in our DCF model from 13% to 12% which led to our Buy rating and $193 PT (up from Neutral and $137, previously)."

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $147.82 yesterday.

You May Also Be Interested In

• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$231 at Bernstein SocGen
• McGraw Hill (MH) PT Lowered to $14 at UBS on Softer 2027 Outlook
• Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR18 at JPMorgan